-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lung cancer is the most common cancer and one of the world's most serious causes of cancer deathEvery year, 2 million patients are diagnosed with lung cancer, and 1.7 million die from lung cancerIn NSCLC patients, about 3%-5% of patients developmet gene amplification or exosome 14 mutationsWith regard to MET mutation, we do not currently have approved targeted therapies, and the prognosis of these patients is not optimisticTepotinib is a highly selective oral MET inhibitor developed by Merck in Germany that shows antitumor activity in patients with NSCLC overexpression or amplification of METIn addition to being used in clinical trials for NSCLC patients, tepotinib is also treating patients with hepatocellular carcinoma in Phase 2 clinical trialsTepotinib Molecular Structure (Photo: PubChem)the breakthrough therapy is based on ongoing Phase 2 clinical studies called VISIONA total of 73 patients with metastatic NSCLC who had been identified by tissue biopsy (TBx) or liquid biopsy (LBx) with a met exoon 14 jump mutation participated in the trialTrial data suggest that tepotinib may improve treatment options for these patientsFor LBx-confirmed patients, the Independent Review Board (IRC) received a total remission rate (ORR) of 50% and the researchers' results were 55.3%For patients confirmed by TBx, the two figures were 45.1% and 54.9%, respectivelyIn terms of median remission duration (DOR), the IRC gave figures of 12.4 months and 15.7 months, respectively, for patients confirmed by LBx and TBxFor both groups of patients, the researchers gave 17.1 months and 14.3 months, respectively"
Tepotinib has shown very encouraging overall remission rates and lasting efficacy in patients with metastasis 14-jumping mutations confirmed by TBx or LBx," said DrLuciano Rosettietti, head of global biomedicine research and development at Merck, Germany We look forward to providing this medicine to Patients with NSCLC who may benefit as soon as possible References: , Merck KGaA, Darmstadt, Germany, Announces FDA's Therapy Therapy Therapy For Therapy Tepotinib in Patients Metastatic NSCLC with METex14 Skipping Alterations, RetrievEd Septembered 11, 2019, from the